PBRM1 and BRD7, which are mutated at lower frequency in melanoma than ARID2 (Table 1, Figure 2), were also identified in an unbiased CRISPR/CAS9 screen as modulators of resistance to T cell-mediated killing and sensitivity to immunotherapy [152]. Here, ARID2 is linked to melanoma.